Message :
Required fields
MORRISVILLE, N.C., May 03, 2021 (GLOBE NEWSWIRE) Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization, today announced it commenced an underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation (the “Selling Stockholders”) of an aggregate of 7,000,000 shares of the Company’s common stock (the “Offering”) pursuant to the Company’s shelf registration statement filed with the Securities and Exchange Commission (“SEC”). The Selling Stockholders intend to grant the underwriter a 30-day option to purchase up to 1,050,000 additional shares of common stock. Syneos Health is not selling any shares and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the Offering.
Illingworth Research Group Recognized with Queen’s Award for Enterprise: International Trade 2021
MORRISVILLE, N.C., April 30, 2021 (GLOBE NEWSWIRE) The Illingworth Research Group, a Syneos Health
® company, has been recognized with a 2021 Queen’s Award for Enterprise for International Trade. Illingworth Research Group™ is a leading global provider of clinical research home health services. With healthcare already becoming more local, COVID-19 has accelerated the need for in-home clinical trial services which have realized increasing demand in recent years.
Illingworth is one of only 205 UK-based organizations to be recognized with the prestigious Queen’s Award. With this acknowledgement, Illingworth Research becomes the first organization to be awarded the highly acclaimed industry SCRIP Award as Best Specialist Provider, and a Queens Award for Enterprise: International Trade, in the same year.
Syneos Health expects to ride Covid-related work well into 2021 - Triangle Business Journal bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Highlights
GAAP revenue of $1,140.0 million for the three months ended December 31, 2020, representing a sequential increase of 3.7% compared to the three months ended September 30, 2020.
Net new business awards of $1,764.1 million and $5,863.1 million for the three and twelve months ended December 31, 2020, representing book-to-bill ratios of 1.55x and 1.33x, respectively.
Clinical Solutions segment net new business awards of $1,299.3 million and $4,698.7 million for the three and twelve months ended December 31, 2020, representing book-to-bill ratios of 1.52x and 1.42x, respectively, and year-over-year backlog growth of 24.6% as of December 31, 2020.
Commercial Solutions segment net new business awards of $464.8 million and $1,164.4 million for the three and twelve months ended December 31, 2020, representing book-to-bill ratios of 1.63x and 1.05x, respectively.